Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 33

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 33
---
Zeneca's knowledge, the importation taxes referred to in the Appraisal Opinion relate to Enhertu.                                                                                                                                                                                                                                                                                    
 - A fine of between one and five times the amount of unpaid importation taxes may also be levied if AstraZeneca is found liable.                                                                                                                                                                                                                                                                           | ​ |
| China Personal Information Infringement                                                                                                                                     
 Considered to be a contingent liability                                                                                                                                     | - In relation to the personal information infringement allegation, in April 2025, AstraZeneca received a Notice of Transfer to the Prosecutor from the Shenzhen Bao'an District Public Security Bureau (the PSB) regarding suspected unlawful collection of personal information.                                                                                                                          
 - The Company has been informed that there was no illegal gain to the Company resulting from personal information infringement.                                                                                                                                                                                                                                                                            | ​ |

44

Note 6: Analysis of Revenue and Other operating income and expense

Table 23: Product Sales year-on-year analysis: H1 2025

The CER information in respect of H1 2025 included in the Interim financial statements has not been reviewed by PricewaterhouseCoopers LLP.

| ​                               
 ​                               
 For the half year ended 30 June | ​ 
 ​ 
 ​ |      ​ 
  World 
      ​ | ​ 
 ​ |      ​ 
 Change | ​ |     ​ | ​ 
 ​ 
 ​ |      ​ 
     US 
      ​ | ​ 
 ​ |      ​ 
 Change | ​ 
 ​ 
 ​ |                ​ 
 Emerging Markets 
                ​ | ​ 
 ​ |      ​ 
 Change | ​ |     ​ | ​ 
 ​ 
 ​ |      ​ 
 Europe 
      ​ | ​ 
 ​ |      ​ 
 Change | ​ |     ​ | ​ 
 ​ 
 ​ |               ​ 
 Established RoW 
               ​ | ​ 
 ​ |      ​ 
 Change | ​ |     ​ |
|:--------------------------------|:--|-------:|:--|-------:|:--|------:|:--|-------:|:--|-------:|:--|-----------------:|:--|-------:|:--|------:|:--|-------:|:--|-------:|:--|------:|:--|----------------:|:--|-------:|:--|------:|
| ​                               |   |     $m |   |  Act % |   | CER % |   |     $m |   |  Act % |   |               $m |